Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
Uro-Oncology
Related content
COMMENTED
Uro-Oncology
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
★ 3
Recommended by
Alexander Meisel, Faculty Member
Eur Urol.
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators.
doi: 10.1016/j.eururo.2019.09.019.
Uro-Oncology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Prostate Cancer Prostatic Dis
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI
doi: 10.1038/s41391-021-00395-4
Uro-Oncology
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
Lancet
Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, Massard C, Matsubara N, Alekseev B, Parnis F, Atduev V, Buchschacher GL Jr, Gafanov R, Corrales L, Borre M, Stroyakovskiy D, Alves GV, Bournakis E, Puente J, Harle-Yge ML, Gallo J, Chen G, Hanover J, Wongchenko MJ, Garcia J, de Bono JS
doi: 10.1016/S0140-6736(21)00580-8
Uro-Oncology
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III)
J Urol.
Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY, Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR III) Group
doi: 10.1016/j.juro.2018.05.164.
COMMENTED
Uro-Oncology
New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Urol.
Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul A, Veccia A, Autorino R, Cindolo L, Schips L
doi: 10.1097/JU.0000000000000636.
Uro-Oncology
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Eur J Cancer.
Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE
doi: 10.1016/j.ejca.2016.10.020.
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.
Uro-Oncology
Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data
Prostate Cancer Prostatic Dis
Martini A, Parikh AB, Sfakianos JP, Montorsi F, Galsky MD, Oh WK, Tsao CK
doi: 10.1038/s41391-021-00326-3
Uro-Oncology
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
Prostate Cancer Prostatic Dis
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS
doi: 10.1038/s41391-021-00465-7